Literature DB >> 7771023

Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.

S S Taneja1, W Pierce, R Figlin, A Belldegrun.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7771023     DOI: 10.1016/s0090-4295(99)80108-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  5 in total

Review 1.  Combination of surgery and immunotherapy in metastatic renal cell carcinoma.

Authors:  Gerald H Mickisch; Roland H Mattes
Journal:  World J Urol       Date:  2005-03-25       Impact factor: 4.226

2.  A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon.

Authors:  Ken-Ryu Han; Allan J Pantuck; Arie S Belldegrun
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 3.092

3.  In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Authors:  J S Economou; A S Belldegrun; J Glaspy; E M Toloza; R Figlin; J Hobbs; N Meldon; R Kaboo; C L Tso; A Miller; R Lau; W McBride; R C Moen
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

4.  Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma.

Authors:  P F Geertsen; M E Gore; S Negrier; J M Tourani; H von der Maase
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

5.  Is Curfew Effective in Limiting SARS-CoV-2 Progression? An Evaluation in France Based on Epidemiokinetic Analyses.

Authors:  Bruno Mégarbane; Fanchon Bourasset; Jean-Michel Scherrmann
Journal:  J Gen Intern Med       Date:  2021-06-15       Impact factor: 5.128

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.